France; Panacea Pharmaceuticals Inc

Gaithersburg, United States

France; Panacea Pharmaceuticals Inc

Gaithersburg, United States

Time filter

Source Type

PubMed | France; Panacea Pharmaceuticals Inc
Type: Journal Article | Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2016

22135 Background: The human aspartyl (asparaginyl) -hydroxylase (HAAH) is a highly conserved enzyme that hydroxylates epidermal growth factor-like domains in transformation-associated proteins. It was recently reported that the serum HAAH level in lung cancer can facilitate an earlier diagnosis of lung cancer and increase the rate of survival (Specificity amongst smokers of 90% and sensitivity of 98%). In this study we firstly compared HAAH serum levels in NSCLC patients vs. healthy individuals. Subsequently a follow-up of this marker was made in order to understand the possible implication of this protein with clinical response to treatment.Using an experimental double monoclonal antibody sandwich ELISA, HAAH level was measured in the sera of 46 patients with non small cell lung cancer (NSCLC) in comparison to 15 healthy controls. A further follow-up of HAAH level was performed on 22 patients before and after the treatment.Serum HAAH was detectable and variable in 92% of NSCLC patients (n=43). Serum HAAH was found to be undetectable in healthy donors. When patients were compared to healthy donors the pretreatment median level of serum HAAH was significantly higher in NSCLC patients (P=0.00059). HAAH level did not correlate with gender or age. At the end of the treatment a decrease of HAAH level was noted. When patients were classified according to the clinical response pre-treatment HAAH levels were higher in patients that had progressive disease despite treatment (n=19) as compared to responder (n=9) or stable disease patients (n=14). At the end of treatment, a decrease of serum HAAH level was noted specifically in responder patients.Our results suggest that determination of pre-treatment serum HAAH levels could be helpful in the stratification of patients according to their clinical response and their follow-up. Due to the small number of patients, these results must be considered preliminary and a study in a higher number of patients is ongoing in order to confirm these interesting results. [Table: see text].

Loading France; Panacea Pharmaceuticals Inc collaborators
Loading France; Panacea Pharmaceuticals Inc collaborators